{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T01:47:14Z","timestamp":1768700834791,"version":"3.49.0"},"reference-count":81,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003321","name":"Queen\u2019s University","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100003321","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000033","name":"Institute of Musculoskeletal Health and Arthritis","doi-asserted-by":"publisher","award":["PJT-191711"],"award-info":[{"award-number":["PJT-191711"]}],"id":[{"id":"10.13039\/501100000033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,6,10]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Fibromyalgia is associated with chronic widespread pain and disturbed sleep. Multidisciplinary, multimodal management often includes pharmacotherapy; however, current drugs used to treat fibromyalgia provide meaningful benefit to only 30\u201360% of treated individuals. Combining two or more different drugs is common in clinical practice with the expectation of better efficacy, tolerability or both; however, further research is needed to identify which combinations actually provide added benefit. Thus, we are planning a clinical trial to evaluate melatonin (MLT)\u2013pregabalin (PGB) combination in participants with fibromyalgia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This will be a single-centre, double-blind, randomised, double-dummy, three-period, crossover trial comparing a MLT\u2013PGB combination to each monotherapy in 54 adult participants satisfying the 2016 American College of Rheumatology criteria for fibromyalgia. Participants will receive maximally tolerated doses of MLT, PGB and MLT\u2013PGB combination for 6 weeks. The primary outcome will be daily pain intensity (0\u201310); secondary outcomes will include the Fibromyalgia Impact Questionnaire, SF-36 survey, Medical Outcomes Study Sleep Scale, Beck Depression Inventory (BDI-II), adverse events and other measures. Analysis of the primary and secondary outcomes will involve a linear mixed model with sequence, period, treatment, the first-order carryover and baseline pain score as fixed effects and participant as a random effect to test whether there are any treatment differences among three treatments and to estimate the least square mean of the mean daily pain intensity for each treatment, adjusting for carryover as well as period effects (ie, stability of pain levels).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This trial has been registered with the International Standard Randomised Controlled Trial Number Registry, ISRCTN #18278231, has been granted ethical approval by the Queen\u2019s University Health Sciences Research Ethics Board (Queen\u2019s HSREB Protocol #6040998) and is currently under review for a Clinical Trial Application to Health Canada Natural and Non-prescription Health Products Directorate. All participants will provide written informed consent prior to trial participation. Following trial completion, results will be disseminated in one or more biomedical journal publications and presented at one or more scientific meetings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      This trial has been registered with the International Standard Randomised Controlled Trial Number Registry,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN18278231\">ISRCTN18278231<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-087180","type":"journal-article","created":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T10:45:48Z","timestamp":1719139548000},"page":"e087180","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["PRECISE trial (Pain RElief Combination Intervention StratEgies): protocol for the clinical trial of a pregabalin\u2013melatonin combination for fibromyalgia"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"isrctn18278231","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5293-8792","authenticated-orcid":false,"given":"Ian","family":"Gilron","sequence":"first","affiliation":[{"name":"Kingston Health Sciences Centre, Kingston, Ontario, Canada"},{"name":"Providence Care Hospital, Kingston, Ontario, Canada"},{"name":"Department of Biomedical & Molecular Sciences, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"DeBow","sequence":"additional","affiliation":[{"name":"Arcus Analytica, Halifax, Nova Scotia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala","family":"Elkerdawy","sequence":"additional","affiliation":[{"name":"Kingston Health Sciences Centre, Kingston, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S","family":"Khan","sequence":"additional","affiliation":[{"name":"ANESTHESIOLOGY and Pain Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim V","family":"Salomons","sequence":"additional","affiliation":[{"name":"Psychology, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Duggan","sequence":"additional","affiliation":[{"name":"Kingston Health Sciences Centre, Kingston, Ontario, Canada"},{"name":"Department of Biomedical & Molecular Sciences, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Tu","sequence":"additional","affiliation":[{"name":"Canadian Cancer Trials Group, Queens University at Kingston, Kingston, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9070-2510","authenticated-orcid":false,"given":"Ronald R","family":"Holden","sequence":"additional","affiliation":[{"name":"Department of Psychology, Queen's University, Kingston, Ontario, Canada"},{"name":"Department of Psychiatry, Providence Care Hospital, Kingston, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roumen","family":"Milev","sequence":"additional","affiliation":[{"name":"Department of Psychology, Queen's University, Kingston, Ontario, Canada"},{"name":"Department of Psychiatry, Providence Care Hospital, Kingston, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D Norman","family":"Buckley","sequence":"additional","affiliation":[{"name":"Anesthesia, McMaster University, Hamilon, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwight E","family":"Moulin","sequence":"additional","affiliation":[{"name":"Clinical Neurological Sciences and Oncology, Western University, London, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,6,23]]},"reference":[{"key":"2025121400305442000_14.6.e087180.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3266"},{"key":"2025121400305442000_14.6.e087180.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.08.012"},{"key":"2025121400305442000_14.6.e087180.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2016.12.006"},{"key":"2025121400305442000_14.6.e087180.4","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(92)90145-2"},{"key":"2025121400305442000_14.6.e087180.5","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000902"},{"key":"2025121400305442000_14.6.e087180.6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/14728214.2014.915025","article-title":"Emerging drugs for neuropathic pain","volume":"19","author":"Gilron","year":"2014","journal-title":"Expert Opin Emerg Drugs"},{"key":"2025121400305442000_14.6.e087180.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.944"},{"key":"2025121400305442000_14.6.e087180.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.05.014"},{"key":"2025121400305442000_14.6.e087180.9","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-8-29","article-title":"Duloxetine for painful diabetic neuropathy and Fibromyalgia pain: systematic review of randomised trials","volume":"8","author":"Sultan","year":"2008","journal-title":"BMC Neurol"},{"key":"2025121400305442000_14.6.e087180.10","article-title":"Combination Pharmacotherapy for the treatment of Fibromyalgia in adults","volume":"2","author":"Thorpe","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121400305442000_14.6.e087180.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70193-5"},{"key":"2025121400305442000_14.6.e087180.12","article-title":"Combination Pharmacotherapy for the treatment of neuropathic pain in adults","volume":"2012","author":"Chaparro","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121400305442000_14.6.e087180.13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/j.pain.0000000000002688","article-title":"Combination Pharmacotherapy for the treatment of neuropathic pain in adults: systematic review and meta-analysis","volume":"164","author":"Balanaser","year":"2023","journal-title":"Pain"},{"key":"2025121400305442000_14.6.e087180.14","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-008-0068-4"},{"key":"2025121400305442000_14.6.e087180.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01480.x"},{"key":"2025121400305442000_14.6.e087180.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2003.12.004"},{"key":"2025121400305442000_14.6.e087180.17","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"Euro J of Neurology"},{"key":"2025121400305442000_14.6.e087180.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.06.019"},{"key":"2025121400305442000_14.6.e087180.19","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"3","author":"Colloca","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025121400305442000_14.6.e087180.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.01.018"},{"key":"2025121400305442000_14.6.e087180.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(96)03226-5"},{"key":"2025121400305442000_14.6.e087180.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.09.002"},{"key":"2025121400305442000_14.6.e087180.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2013.08.007"},{"key":"2025121400305442000_14.6.e087180.24","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001786"},{"key":"2025121400305442000_14.6.e087180.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.01.001"},{"key":"2025121400305442000_14.6.e087180.26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.smrv.2013.07.005","article-title":"A review of the effects of Pregabalin on sleep disturbance across multiple clinical conditions","volume":"18","author":"Roth","year":"2014","journal-title":"Sleep Med Rev"},{"key":"2025121400305442000_14.6.e087180.27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jab.2018.01.005","article-title":"Oral melatonin administration improves the objective and subjective sleep quality, increases 6-Sulfatoxymelatonin levels and total antioxidant capacity in patients with Fibromyalgia","volume":"16","author":"Yolanda Casta\u00f1o","year":"2018","journal-title":"J Appl Biomed"},{"key":"2025121400305442000_14.6.e087180.28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/acr.21595","article-title":"Effect of Pregabalin on sleep in patients with Fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover Polysomnography study","volume":"64","author":"Roth","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2025121400305442000_14.6.e087180.29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1600-079X.2010.00836.x","article-title":"Adjuvant use of melatonin for treatment of Fibromyalgia","volume":"50","author":"Hussain","year":"2011","journal-title":"J Pineal Res"},{"key":"2025121400305442000_14.6.e087180.30","unstructured":"Health Canada, notice of compliance for Lyrica[Pregabalin]. 2009. Available: http:\/\/205.193.93.51b\/NocWeb\/"},{"key":"2025121400305442000_14.6.e087180.31","doi-asserted-by":"crossref","unstructured":"Moore RA , Straube S , Wiffen PJ , et al . Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009. doi:10.1002\/14651858.CD007076.pub2","DOI":"10.1002\/14651858.CD007076.pub2"},{"key":"2025121400305442000_14.6.e087180.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctcp.2019.101072","article-title":"Melatonin in the treatment of Fibromyalgia symptoms: A systematic review","volume":"38","author":"Hemati","year":"2020","journal-title":"Complement Ther Clin Pract"},{"key":"2025121400305442000_14.6.e087180.33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/2050-6511-15-40","article-title":"Melatonin analgesia is associated with improvement of the descending endogenous pain-Modulating system in Fibromyalgia: a phase II, randomized, double-dummy, controlled trial","volume":"15","author":"de Zanette","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"2025121400305442000_14.6.e087180.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063773","article-title":"Meta-analysis: melatonin for the treatment of primary sleep disorders","volume":"8","author":"Ferracioli-Oda","year":"2013","journal-title":"PLoS One"},{"key":"2025121400305442000_14.6.e087180.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(01)00172-1"},{"key":"2025121400305442000_14.6.e087180.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(98)00890-7"},{"key":"2025121400305442000_14.6.e087180.37","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-06-01868.2001"},{"key":"2025121400305442000_14.6.e087180.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.09.008"},{"key":"2025121400305442000_14.6.e087180.39","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/754693"},{"key":"2025121400305442000_14.6.e087180.40","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"2025121400305442000_14.6.e087180.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209724"},{"key":"2025121400305442000_14.6.e087180.42","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/918216"},{"key":"2025121400305442000_14.6.e087180.43","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/j.pain.0000000000000558","article-title":"Combination of Pregabalin with Duloxetine for Fibromyalgia: a randomized controlled trial","volume":"157","author":"Gilron","year":"2016","journal-title":"Pain"},{"key":"2025121400305442000_14.6.e087180.44","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e3181fe13f6"},{"key":"2025121400305442000_14.6.e087180.45","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1097\/j.pain.0000000000002875","article-title":"Combination analgesic development for enhanced clinical efficacy (the CADENCE trial): a double-blind, controlled trial of an alpha-Lipoic acid-Pregabalin combination for Fibromyalgia pain","volume":"164","author":"Gilron","year":"2023","journal-title":"Pain"},{"key":"2025121400305442000_14.6.e087180.46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/j.pain.0000000000003038","article-title":"Randomized, double-blind, controlled trial of a combination of alpha-Lipoic acid and Pregabalin for neuropathic pain: the PAIN-CARE trial","volume":"165","author":"Gilron","year":"2024","journal-title":"Pain"},{"key":"2025121400305442000_14.6.e087180.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701163360306"},{"key":"2025121400305442000_14.6.e087180.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2009.01.024"},{"key":"2025121400305442000_14.6.e087180.49","unstructured":"Health Canada Melatonin Monograph, Available: http:\/\/webprod.hc-sc.gc.ca\/nhpidbdipsn\/ atReq.do?atid=melatonin.oral&lang=eng"},{"key":"2025121400305442000_14.6.e087180.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042580"},{"key":"2025121400305442000_14.6.e087180.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61081-3"},{"key":"2025121400305442000_14.6.e087180.52","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/j.pain.0000000000000149","article-title":"Combination of morphine with nortriptyline for neuropathic pain","volume":"156","author":"Gilron","year":"2015","journal-title":"Pain"},{"key":"2025121400305442000_14.6.e087180.53","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.j.pain.0000460311.71572.5f","article-title":"Selective melatonin Mt2 receptor ligands relieve neuropathic pain through modulation of brainstem descending Antinociceptive pathways","volume":"156","author":"Lopez-Canul","year":"2015","journal-title":"Pain"},{"key":"2025121400305442000_14.6.e087180.54","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3389\/fphar.2018.00587","article-title":"M'Dahoma et al, \u03912- and \u03922-Adrenoreceptor-mediated efficacy of the atypical antidepressant Agomelatine combined with Gabapentin to suppress allodynia in neuropathic rats with Ligated Infraorbital or Sciatic nerve","volume":"9","author":"M\u2019Dahoma","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025121400305442000_14.6.e087180.55","doi-asserted-by":"crossref","first-page":"117095","DOI":"10.1016\/j.lfs.2019.117095","article-title":"Study of the possible synergistic protective effects of melatonin and Pregabalin in vincristine induced peripheral neuropathy Wistar Albino rats","volume":"244","author":"Soliman","year":"2020","journal-title":"Life Sciences"},{"key":"2025121400305442000_14.6.e087180.56","unstructured":"Spilker B . Combination medicine trials. In: Spilker B , ed. Guide to clinical trials. New York: Raven Press, 1991."},{"key":"2025121400305442000_14.6.e087180.57","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(97)00041-9"},{"key":"2025121400305442000_14.6.e087180.58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.0013-9580.2004.455003.x","article-title":"Pregabalin pharmacology and its relevance to clinical practice","volume":"45 Suppl 6","author":"Ben-Menachem","year":"2004","journal-title":"Epilepsia"},{"key":"2025121400305442000_14.6.e087180.59","doi-asserted-by":"publisher","DOI":"10.1213\/01.ane.0000287643.13410.5e"},{"key":"2025121400305442000_14.6.e087180.60","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0b013e3282effaa7"},{"key":"2025121400305442000_14.6.e087180.61","doi-asserted-by":"publisher","DOI":"10.1126\/science.1167425"},{"key":"2025121400305442000_14.6.e087180.62","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X14666161228122115"},{"key":"2025121400305442000_14.6.e087180.63","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1873-4"},{"key":"2025121400305442000_14.6.e087180.64","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01933.x"},{"key":"2025121400305442000_14.6.e087180.65","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0908-7"},{"key":"2025121400305442000_14.6.e087180.66","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008318669"},{"key":"2025121400305442000_14.6.e087180.67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mcp.2000.104071","article-title":"Increased Bioavailability of oral melatonin after fluvoxamine coadministration","volume":"67","author":"Hartter","year":"2000","journal-title":"Clin Pharm Therap"},{"key":"2025121400305442000_14.6.e087180.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.09.012"},{"key":"2025121400305442000_14.6.e087180.69","first-page":"S154","article-title":"The Fibromyalgia impact questionnaire (FIQ): a review of its development, current version, operating characteristics and uses","volume":"23","author":"Bennett","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025121400305442000_14.6.e087180.70","unstructured":"Hays RD , Stewart AL . Sleep measures. In: Stewart AL , Ware JEJ , eds. Measuring functioning and well-being. Durham: Duke University Press, 1992: 232\u201359."},{"key":"2025121400305442000_14.6.e087180.71","first-page":"129","article-title":"Pain assessment: global use of the brief pain inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"2025121400305442000_14.6.e087180.72","doi-asserted-by":"crossref","unstructured":"Beck A , Steer R , Brown G . BDI-II: Beck Depression Inventory Manual\u2014Second Edition. The Psychological Corporation, Harcourt Brace & Company, 1996.","DOI":"10.1037\/t00742-000"},{"key":"2025121400305442000_14.6.e087180.73","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1995.76.2.459"},{"key":"2025121400305442000_14.6.e087180.74","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(87)91074-8"},{"key":"2025121400305442000_14.6.e087180.75","unstructured":"Ware JE , Snow KK , Kosinski M , et al . SF-36 Health Survey Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Centre, 1993."},{"key":"2025121400305442000_14.6.e087180.76","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00349-9"},{"key":"2025121400305442000_14.6.e087180.77","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0197-2456(02)00317-3","article-title":"Sample size calculation for Bioequivalence studies with high-order crossover designs","volume":"24","author":"Qu","year":"2003","journal-title":"Control Clin Trials"},{"key":"2025121400305442000_14.6.e087180.78","doi-asserted-by":"crossref","unstructured":"Fairclough DL . Analyzing Studies with Missing Data, in Assessing Quality of Life in Clinical Trials. 2nd edn. Oxford University Press, 2005:182.","DOI":"10.1093\/oso\/9780198527695.003.0012"},{"key":"2025121400305442000_14.6.e087180.79","doi-asserted-by":"crossref","unstructured":"Jones B , Kenward MG . Design and analysis of cross-over trials. In: Design and analysis of cross-over trials. Boca Raton: Second Edition, Chapman & Hall\/CRC, 2003. Available: https:\/\/www.taylorfrancis.com\/books\/9781420036091","DOI":"10.1201\/9781420036091"},{"key":"2025121400305442000_14.6.e087180.80","unstructured":"Hochberg Y , Tamhane AC . Multiple Comparison Procedures. New York: Wiley, Available: https:\/\/onlinelibrary.wiley.com\/doi\/book\/10.1002\/9780470316672"},{"key":"2025121400305442000_14.6.e087180.81","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/87.3.507"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-087180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:31:08Z","timestamp":1765701068000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-087180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":81,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,23]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/bmjopen-2024-087180"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-087180","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}